Pelvic floor problems are common, underreported, and almost universally undertreated. Surveys consistently find that fewer than a quarter of women with urinary leakage have sought help for it, most citing embarrassment or assuming nothing can be done.[1] Both assumptions are wrong: pelvic floor dysfunction is treatable, and specialised physiotherapy (the most effective treatment) produces results that surgery often cannot match for less severe presentations.

In perimenopause and menopause, pelvic floor problems become more prevalent for specific reasons. Understanding the mechanism informs the treatment.

What the Pelvic Floor Is

The pelvic floor is a group of muscles, ligaments, and connective tissue forming the base of the pelvis. These structures support the bladder, bowel, and uterus; control the sphincters that manage urine and bowel function; contribute to sexual sensation and orgasm; and coordinate with the diaphragm, deep abdominal muscles, and spinal muscles as part of the core stability system.

The muscles can be too tight (hypertonic), too weak, or poorly coordinated. All three presentations cause problems. Treating weakness in a hypertonic pelvic floor can make symptoms worse. This is why generic Kegel advice, applied without assessment, sometimes fails or worsens pain: not because Kegels are wrong, but because they are the right tool for one presentation and the wrong tool for another.

How Estrogen Affects Pelvic Floor Tissues

Estrogen receptors are present throughout the pelvic floor: in the vaginal walls, the urethra, the bladder, the pelvic floor muscles, and the connective tissue and fascia that support the pelvic organs.[2]

Collagen synthesis. Estrogen promotes the production and organisation of collagen in connective tissue. Collagen is the structural protein that gives support tissues their tensile strength. As estrogen falls, collagen turnover shifts: less is produced, and the remaining collagen becomes less well-organised. The result is reduced connective tissue integrity throughout the body, including in the pelvic support structures.[3]

Mucosal thickness. The vaginal wall and urethral lining are maintained by estrogen. Without it, these tissues thin and become less elastic. The urethral mucosa contributes to the continence mechanism: a well-supplied urethral lining creates a tight seal; an atrophied one does not. This explains why urge and stress urinary incontinence increase after menopause.[4]

Muscle quality. Pelvic floor muscles are maintained partly by sex hormones. Low estrogen is associated with reduced muscle fibre cross-sectional area and reduced strength, independent of the effects on connective tissue.[5]

Innervation. The nerves controlling pelvic floor function are also influenced by estrogen. Estrogen supports nerve conduction velocity and the health of the pudendal nerve, the primary nerve serving the pelvic floor. Declining estrogen may reduce the proprioceptive awareness that makes pelvic floor exercises harder to perform effectively in menopause.[6]

What Symptoms Look Like

Pelvic floor dysfunction in perimenopause and menopause presents in several overlapping patterns.

Stress urinary incontinence (SUI): leakage triggered by a rise in intraabdominal pressure: coughing, sneezing, laughing, jumping, lifting. The urethral closure mechanism is insufficient to withstand the pressure spike. SUI is the most common type of incontinence overall, and its prevalence increases after menopause.[7]

Urge urinary incontinence (UUI): a sudden, intense urge to urinate that is difficult to suppress, sometimes followed by leakage before reaching the toilet. Caused by involuntary detrusor contractions. Often worsens with caffeine, alcohol, and bladder irritants. More closely related to bladder mucosal changes and innervation than to pelvic floor muscle weakness.

Mixed incontinence: symptoms of both SUI and UUI, which frequently co-occur.

Pelvic organ prolapse: the descent of one or more pelvic organs (bladder, uterus, rectum) into or through the vaginal canal, due to weakness in the support structures. Symptoms include a feeling of pressure, heaviness, or "something coming down," lower back discomfort, difficulty emptying the bladder or bowel, and sometimes a visible or palpable bulge. Prolapse ranges from asymptomatic (discovered on examination) to significantly impairing.

Pelvic pain and hypertonicity: muscle tension causing pain with penetration (dyspareunia), pelvic heaviness, difficulty emptying the bladder fully, or vulvar pain. This pattern often coexists with GSM (genitourinary syndrome of menopause) and can be worsened by strengthening exercises performed on already-tight muscles.

When to Seek Help

Any of the above symptoms are reasons to see a GP or women's health physiotherapist. Prioritise:

  • Leakage that affects daily activities, social engagement, or sleep
  • Urgency that is difficult to manage
  • Pelvic pressure or heaviness, particularly after standing for long periods
  • Pain with penetration that is new or worsening
  • Difficulty emptying the bladder or bowel

GPs can refer to women's health physiotherapy on the NHS, and most areas have reasonable access. Waiting times vary but the referral is appropriate for all of the above presentations. Private women's health physiotherapy is available in most cities with typical wait times of one to two weeks.

What Pelvic Floor Physiotherapy Involves

Assessment comes first. A women's health physiotherapist performs an internal assessment (with consent) to determine whether the muscles are weak, hypertonic, or poorly coordinated, and to assess the connective tissue support. A first appointment takes approximately 45–60 minutes. The assessment determines which intervention is appropriate.

For weakness: a progressive strengthening programme. The exercises are prescribed based on your specific muscle function: the number of repetitions, hold duration, and progression schedule. The physiotherapist teaches you to identify the correct muscles (many women are contracting the wrong muscles when they think they are doing Kegels) and monitors progress at follow-up appointments.

For hypertonicity and pain: manual release techniques, breathing work, and relaxation exercises to reduce excessive muscle tension before any strengthening. Doing Kegels on a hypertonic pelvic floor is counterproductive.

For prolapse: physiotherapy is the first-line treatment for stages 1–2 and reduces symptoms in most women. Stage 3–4 prolapse may require surgical referral, but physiotherapy remains part of management before and after any procedure.

A Cochrane review by Dumoulin et al. (2018) found that pelvic floor muscle training was more effective than no treatment for stress, urge, and mixed incontinence, with cure or improvement rates of 56–70% for stress incontinence.[8]

The Role of Local Estrogen

Local vaginal estrogen is an important adjunct to physiotherapy for many women. Applied directly to the vaginal wall and urethral area, it is absorbed locally with minimal systemic absorption, restoring tissue thickness and elasticity without the systemic effects of HRT.[9]

Local estrogen does not treat pelvic floor muscle weakness or dysfunction; it restores the tissue quality in which those muscles operate. For women with GSM-related urethral atrophy contributing to urgency or incontinence, local estrogen is frequently the more targeted intervention. For women with stress incontinence driven by muscle and connective tissue weakness, physiotherapy remains central, but local estrogen supports the tissue environment.

NICE guidelines (2019) recommend that women with urinary incontinence in the context of vaginal atrophy be offered vaginal estrogen before progressing to other treatments.[10]

Local vaginal estrogen is safe for long-term use, including in most women with a history of estrogen-sensitive breast cancer based on current evidence, though this should be discussed with an oncologist for individual risk assessment.

Practical Steps

  1. See a GP to document symptoms and get a referral to women's health physiotherapy.
  2. Do not try to self-manage with generic Kegel advice before assessment; you may have hypertonicity rather than weakness.
  3. If you have symptoms of vaginal dryness or urethral irritability alongside continence symptoms, ask about local vaginal estrogen as a separate, complementary intervention.
  4. If you are on systemic HRT, this addresses some tissue quality mechanisms, but pelvic floor physiotherapy is still the specific treatment for muscle and support structure dysfunction.
  5. Physiotherapy typically requires 3–6 months of consistent home exercise for meaningful improvement in incontinence. Prolapse symptoms improve more slowly.

References

[1] Minassian, V. A., Bazi, T., Stewart, W. F. (2017). Clinical epidemiological insights into urinary incontinence. International Urogynecology Journal, 28(5), 687–696. https://doi.org/10.1007/s00192-017-3314-7

[2] Gebhart, J. B., Rickard, D. J., Barrett, T. J., et al. (2001). Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. American Journal of Obstetrics and Gynecology, 185(6), 1325–1330. https://doi.org/10.1067/mob.2001.119498

[3] Brincat, M. P. (2000). Hormone replacement therapy and the skin. Maturitas, 35(2), 107–117. https://doi.org/10.1016/s0378-5122(00)00097-x

[4] Perucchini, D., DeLancey, J. O., Ashton-Miller, J. A., Peschers, U., Kataria, T. (2002). Age effects on urethral striated muscle. I: Changes in number and diameter of striated muscle fibers in the ventral urethra. American Journal of Obstetrics and Gynecology, 186(3), 351–355. https://doi.org/10.1067/mob.2002.121820

[5] Moalli, P. A., Talarico, L. C., Bhavani, V. K., et al. (2004). Impact of menopause on collagen subtypes in the arcus tendineous fasciae pelvis. American Journal of Obstetrics and Gynecology, 190(3), 620–627. https://doi.org/10.1016/j.ajog.2003.10.004

[6] Smith, P. P., McCrery, R. J., Appell, R. A. (2006). Current trends in the evaluation and management of female urinary incontinence. Canadian Medical Association Journal, 175(10), 1233–1240. https://doi.org/10.1503/cmaj.060034

[7] Hannestad, Y. S., Rortveit, G., Sandvik, H., Hunskaar, S. (2000). A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT study. Journal of Clinical Epidemiology, 53(11), 1150–1157. https://doi.org/10.1016/s0895-4356(00)00232-8

[8] Dumoulin, C., Cacciari, L. P., Hay-Smith, E. J. C. (2018). Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database of Systematic Reviews, 10, CD005654. https://doi.org/10.1002/14651858.CD005654.pub4

[9] Suckling, J., Lethaby, A., Kennedy, R. (2006). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews, 4, CD001500. https://doi.org/10.1002/14651858.CD001500.pub2

[10] National Institute for Health and Care Excellence. (2019). Urinary incontinence and pelvic organ prolapse in women: Management (NICE guideline NG123). NICE. https://www.nice.org.uk/guidance/ng123